Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay.

  title={Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay.},
  author={Kelly M MacArthur and Gary D. Kao and Sanjay Chandrasekaran and Michelle Alonso-Basanta and Christina Hunter Chapman and Robert A Lustig and E. Paul Wileyto and Stephen M. Hahn and Jay F. Dorsey},
  journal={Cancer research},
  volume={74 8},
Blood tests to detect circulating tumor cells (CTC) offer great potential to monitor disease status, gauge prognosis, and guide treatment decisions for patients with cancer. For patients with brain tumors, such as aggressive glioblastoma multiforme, CTC assays are needed that do not rely on expression of cancer cell surface biomarkers like epithelial cell adhesion molecules that brain tumors tend to lack. Here, we describe a strategy to detect CTC based on telomerase activity, which is elevated… 

Figures and Tables from this paper

Telomerase-positive circulating tumor cells are associated with poor prognosis via a neutrophil-mediated inflammatory immune environment in glioma

Gliomas are the most common aggressive cancer in the central nervous system. Considering the difficulty in monitoring glioma response and progression, an approach is needed to evaluate the

Current Understanding of Circulating Tumor Cells – Potential Value in Malignancies of the Central Nervous System

This review examines methods for CTC enrichment and detection, and reviews the progress in non-CNS tumors and the potential for using this technique in human brain tumors.

Circulating tumor cells and extracellular vesicles as liquid biopsy markers in neuro-oncology: prospects and limitations

The emerging aspects of CTCs and EVs as liquid biopsy biomarkers in neuro-oncology are reviewed, including glioblastoma EVs, which being shed by tumor cells and microenvironment and being more diffusible than C TCs may yield a more complete reflection of the whole tumor.

Isolation of Circulating Tumor Cells from Glioblastoma Patients by Direct Immunomagnetic Targeting

Glioblastoma (GBM) is the most common form of primary brain cancer in adults and tissue biopsies for diagnostic purposes are often inaccessible. The postulated idea that brain cancer cells cannot

Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord

It is shown here that primary CNS malignancies shed detectable levels of tumor DNA into the surrounding cerebrospinal fluid (CSF), which could serve as a sensitive and exquisitely specific marker for quantifying tumor burden without invasive biopsies.

Blood-based biomarkers for the diagnosis and monitoring of gliomas.

The ability to obtain serial "liquid biopsies" will provide unique opportunities to study the evolution of tumors and mechanisms of treatment resistance and monitor for mutational changes in response to therapy.

Liquid Biopsy and Primary Brain Tumors

The promises, developments, and challenges related to liquid biopsy of brain tumors, including circulating tumor cells, cell-free nucleic acids, extracellular vesicles, and miRNA are highlighted; the urgent need to establish suitable biomarkers and the right standards to improve modern clinical management of brain tumor patients with the use of liquidBiopsy is discussed.

A Novel Approach for the Detection and Genetic Analysis of Live Melanoma Circulating Tumor Cells

This is the first report of a telomerase-based assay effective for detecting and isolating live melanoma CTCs and these promising findings support further studies, including towards integrating into the management of patients with melanoma receiving multimodality therapy.

Next generation sequencing of glioblastoma circulating tumor cells: non-invasive solution for disease monitoring.

The results confirm the feasibility of using CTCs as a source of tumor DNA in a diagnostic process, especially when evaluating the molecular characteristics of GBMs.

Circulating tumor cell is a common property of brain glioma and promotes the monitoring system

Clinical data revealed that CTCs, to some extent, was superior to MRI in monitoring the treatment response and differentiating radionecrosis from recurrence of glioma, which has provided an ultimate paradox for the hypothesis “soil and seed”.



High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity.

  • K. FizaziL. Morat J. Soria
  • Medicine, Biology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2007
CTCs can be detected using telomerase activity in a large majority and a wide variety of patients with prostate cancer, including those with localized disease.

Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients.

  • J. SoriaL. Gauthier L. Sabatier
  • Biology, Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1999
The detection of circulating tumor cells and micrometastases may have important therapeutic and prognostic implications. Telomerase is a hallmark of cancer and is absent from normal epithelial cells.

A simple biological imaging system for detecting viable human circulating tumor cells.

This work reports what they believe to be a new approach to visually detect live human CTCs among millions of peripheral blood leukocytes, using a telomerase-specific replication-selective adenovirus expressing GFP.

A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter.

A novel cancer detection platform which measures telomerase activity from live CTCs captured on a parylene-C slot microfilter, capable of cell capture from 1 mL of whole blood in less than 5 minutes, achieving 90% capture efficiency, 90% cell viability, and 200-fold sample enrichment.

Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients

The authors' data indicate that a major proportion of CTC of metastatic breast cancer patients shows EMT and tumor stem cell characteristics, and further studies are needed to prove whether these markers might serve as an indicator for therapy resistant tumor cell populations and, therefore, an inferior prognosis.

Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal

The presence of mesenchymal markers on CTC more accurately predicted worse prognosis than the expression of cytokeratins alone and assays targeting epithelial antigens may miss the most invasive cell population.

Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases

The CellSearch system can be standardized across multiple laboratories and may be used to determine the clinical utility of CTCs, which are extremely rare in healthy subjects and patients with nonmalignant diseases but present in various metastatic carcinomas with a wide range of frequencies.

Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood

A micro-fluidic system, not limited to EpCAM or CK, was developed to use multiple antibodies for capture followed by detection using CEE-Enhanced (CE), a novel in situ staining method that fluorescently labels the capture antibodies bound to CTCs.

Visualization of Intrathoracically Disseminated Solid Tumors in Mice with Optical Imaging by Telomerase-Specific Amplification of a Transferred Green Fluorescent Protein Gene

This work describes a new approach to visualizing tumors whose fluorescence can be detected using tumor-specific replication-competent adenovirus (OBP-301, Telomelysin) in combination with Ad-GFP, a replication-deficient adenova expressing green fluorescent protein (GFP).